- Palbociclib Plus Fulvestrant in Korean Patients from PALOMA-3 With Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer
-
Kim JH, Im SA, Sim SH, Bananis E, Huang X, Kim HS, Kim SB
- KMID: 2515171
- J Breast Cancer.
- 2021 Feb;24(1):97-105.
- doi: 10.4048/jbc.2021.24.e13
In the PALOMA-3 trial, the median progression-free survival (PFS) was longer among patients with hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2−) advanced breast cancer (ABC) treated with palbociclib... -
- CITED
-
- Close
- SHARE
-
- Close
